LAG3 and neoplasm: Interestingly, preclinical studies in vitro showed that the use of an anti-LAG-3 antibody (REGN3767), alone or in combination with cemiplimab (REGN2810, a human anti-PD-1 antibody), resulted in increased efficacy and higher pro-inflammatory cytokine secretion by tumour-specific TILs, as well as improved survival and eradication of neoplastic cells in a mouse tumour model [390,391,392].